Retinopathy - Pipeline Review, H1 2013

Description: Retinopathy - Pipeline Review, H1 2013

Summary

'Retinopathy - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Retinopathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Retinopathy. Retinopathy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Retinopathy.
- A review of the Retinopathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Retinopathy pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Retinopathy.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Retinopathy pipeline depth and focus of indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Retinopathy Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Retinopathy 7
Retinopathy Therapeutics under Development by Companies 9
Retinopathy Therapeutics under Investigation by Universities/Institutes 11
Early Clinical Stage Products 12
Comparative Analysis 12
Discovery and Pre-Clinical Stage Products 13
Comparative Analysis 13
Feb 14, 2012: Gene Signal And Collaborators Demonstrate Successful Activity Of Topical Aganirsen In Models Of Retinal Neovascular Disease 46
Apr 29, 2008: Acucela Presents Preclinical Data From Retinopathy Study Demonstrating Improvement In Retinal Abnormalities 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 49
Disclaimer 49

List of Tables
Number of Products Under Development for Retinopathy, H1 2013 7
Products under Development for Retinopathy – Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 10
Number of Products under Investigation by Universities/Institutes, H1 2013 11
Comparative Analysis by Early Clinical Stage Development, H1 2013 12
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 13
Products under Development by Companies, H1 2013 14
Products under Investigation by Universities/Institutes, H1 2013 15
Acucela Inc., H1 2013 18
Gene Signal International SA., H1 2013 19
Indus Biotech Private Limited, H1 2013 20
Affichem, H1 2013 21
Resolvyx Pharmaceuticals, Inc, H1 2013 22
SIFI Pharma, H1 2013 23
Eleven Biotherapeutics, H1 2013 24
Assessment by Monotherapy Products, H1 2013 25
Assessment by Stage and Route of Administration, H1 2013 27
Assessment by Stage and Molecule Type, H1 2013 29
Retinopathy Therapeutics – Drug Profile Updates 42
Retinopathy Therapeutics – Discontinued Products 43
Retinopathy Therapeutics – Dormant Products 44

List of Figures
Number of Products under Development for Retinopathy, H1 2013 7
Products under Development for Retinopathy – Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Products under Investigation by Universities/Institutes, H1 2013 11
Early Clinical Stage Products, H1 2013 12
Discovery and Pre-Clinical Stage Products, H1 2013 13
Assessment by Monotherapy Products, H1 2013 25
Assessment by Route of Administration, H1 2013 26
Assessment by Stage and Route of Administration, H1 2013 27
Assessment by Molecule Type, H1 2013 28
Assessment by Stage and Molecule Type, H1 2013 29

Ordering:
Order Online - http://www.researchandmarkets.com/reports/2596058/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Retinopathy - Pipeline Review, H1 2013
Web Address: http://www.researchandmarkets.com/reports/2596058/
Office Code: SCD2ILEY

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof [ ]
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World